Albumin-Binding and Conventional PSMA Ligands in Combination with<sup>161</sup>Tb: Biodistribution, Dosimetry, and Preclinical Therapy-Reference-Cited by-同舟云学术

Albumin-Binding and Conventional PSMA Ligands in Combination with¹⁶¹Tb: Biodistribution, Dosimetry, and Preclinical Therapy

Published:2023-07-13 Issue:10 Volume:64 Page:1625-1631
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Tschan Viviane J.,Busslinger Sarah D.,Bernhardt Peter,Grundler Pascal V.,Zeevaart Jan Rijn,Köster Ulli,van der Meulen Nicholas P.,Schibli Roger,Müller Cristina

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference40 articles.

1. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013

2. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

3. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

4. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

5. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma;Molecular Pharmaceutics;2024-04-29

2. Harnessing the power of f-block elements in radiopharmaceuticals;Nature Reviews Chemistry;2024-04-22

3. [¹⁶¹Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [¹⁷⁷Lu]Lu-PSMA-617;Theranostics;2024

4. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside;Theranostics;2024

5. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?;Theranostics;2024